Drugs / L-Arginin-Hydrochloride
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01052623 | Jan 2010 → Dec 2011 | ataxia telangiectasia | Johann Wolfgang Goethe University Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Arginin-Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01052623 ↗ |
| Route | Intravenous | “L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes.” NCT01052623 ↗ |